To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3CompletedNCT00141336

Pfizer750 enrolled

Overview

To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

750

Conditions

Seizure Disorder, Partial

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have met the inclusion criteria for preceding double-blind study * Have received double-blind study medication and wish to receive open-label pregabalin. Exclusion Criteria: * Cannot have absence seizures

Locations (103)

Outcomes

Primary Outcomes

Safety Tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Tucson, Arizona, United States

Pfizer Investigational Site

Bakersfield, California, United States

Pfizer Investigational Site

Berkeley, California, United States

Pfizer Investigational Site

Concord, California, United States

Pfizer Investigational Site

Covina, California, United States

Pfizer Investigational Site

El Cajon, California, United States

Pfizer Investigational Site

Encino, California, United States

Pfizer Investigational Site

La Mesa, California, United States

Pfizer Investigational Site

Marina Del Ray, California, United States

...and 93 more locations